LMLuisa Mehr

Luisa Mehr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luisa Mehr has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas M. Kany

    Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Campus E8 1, Saarbrücken 66123, Germany

    1 shared publication
  • Franziska Fries

    Saarland University

    1 shared publication
  • Jennifer Herrmann

    Saarland University

    1 shared publication
  • Jörg Haupenthal

    Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Campus E8 1, Saarbrücken 66123, Germany

    1 shared publication
  • Kristin von Peinen

    Helmholtz Centre for Infection Research (HZI), Inhoffenstraße 7, Braunschweig 38124, Germany

    1 shared publication
  • Linda Pätzold

    Institute of Medical Microbiology and Hygiene

    1 shared publication

Latest Publications

  • Open Access

    Structure Elucidation, Biosynthesis and Biological Evaluation of Neosorangicin A, a Member of the Sorangicin Family

    by Franziska Fries, Sebastian Walesch, Rolf Jansen, Kristin von Peinen, Luisa Mehr, Linda Pätzold, Sabrina Karwehl, Andreas M. Kany, Ronald Garcia, Silke Reinecke, et al.

    Antimicrobial resistance represents an escalating global health crisis, with drug-resistant infections predicted to cause up to 10 million deaths annually by 2050, underscoring the urgent need for novel antibiotics. Natural products play a crucial role in the discovery and development of antibiotics, with myxobacteria emerging as a particularly promising source due to their ability to produce structurally diverse and bioactive compounds. One prominent example of antibiotics from myxobacteria are the sorangicins, potent inhibitors of the bacterial RNA polymerase (RNAP). Here, we report the isolation of two unprecedented compounds, neosorangicin A (1) and neosorangioside A (2), from Sorangium cellulosum strain Soce439, elucidated their molecular structures, thereby revealing significant structural variation in comparison to sorangicin, and describe their biosynthetic pathway. Neosorangicin A (1) exhibited strong activity against various Gram-positive bacteria, including potent effects against Mycobacterium tuberculosis and enhanced efficacy on intracellular Staphylococcus aureus. In a murine wound infection model, a head-to-head comparison of neosorangicin A (1) and sorangicin A (3) provided useful insights into how the altered physicochemical properties, arising from the shortened side chain and the lack of the free carboxylic acid of neosorangicin A, influence the in vivo efficacy of sorangicin derivatives.